RIBOCURE PHARMACEUTICALS AB
Live / Registered — Registered (as of 01 Apr 2025)
What this means for you
Registered since 01 Apr 2025. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79389701
- Registration number
- 7741542
- Mark type
- Design + words
- Filed
- 29 Dec 2023
- Published for opposition
- 11 Feb 2025
- Registered
- 01 Apr 2025
- Attorney of record
- Zhi Dong
Goods and services
- Class 005 — Pharmaceuticals: medicines for humans for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; crude drugs being pharmaceutical preparations for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; pharmaceutical preparations for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; chemico-pharmaceutical preparations for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; biological preparations for medical purposes for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; chemical preparations for pharmaceutical purposes for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; chemical preparations for medical purposes for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; drugs for medical purposes, namely, pharmaceutical preparations for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; diagnostic preparations for medical purposes; potassium salts for medical purposes; sodium salts for medical purposes; pharmaceutical preparations for the treatment of cancer; anti-cancer preparations; biological preparations for the treatment of cancer; pharmaceutical preparations and substances for the prevention of cancer; tumor suppressing agents; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for the central nervous system; medicinal preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment of hyperlipidemia; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for treating metabolic disorders; anticoagulants; cardiovascular pharmaceutical preparations; pharmaceutical preparations for ocular or intraocular surgery; depuratives for the body; veterinary preparations for the treatment and diagnosis of gastrointestinal diseases, cardiovascular diseases, metabolic diseases, and liver diseases; pesticides; medical dressings; composite materials for dental purposes; diapers for pets
- Class 042 — Scientific and technological services: technological research in the field of pharmaceutical manufacturing processes and pharmaceutical studies; pharmaceutical drug development services; pharmaceutical product evaluation; pharmaceutical research services; pharmaceutical research and development services; scientific research; chemical research and analysis; development and test of chemical production methods; biochemical research and analysis; development of pharmaceutical preparations and medicines; scientific research in the nature of conducting clinical trials for others; medical research; testing of pharmaceuticals; industrial design
Owner
Prosecution history
- 31 Oct 2025 — FINAL DECISION TRANSACTION PROCESSED BY IB
- 14 Oct 2025 — FINAL DISPOSITION NOTICE SENT TO IB
- 14 Oct 2025 — FINAL DISPOSITION PROCESSED
- 01 Aug 2025 — NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
- 14 Jul 2025 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
- 14 Jul 2025 — NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
- 01 Jul 2025 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 01 Apr 2025 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 01 Apr 2025 — REGISTERED-PRINCIPAL REGISTER
- 11 Feb 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 11 Feb 2025 — PUBLISHED FOR OPPOSITION
- 05 Feb 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 18 Jan 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 10 Jan 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 10 Jan 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE